. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999

Table 2.

Observed changes in HBV DNA and pgRNA during the off-treatment phase in patients from study 211 (FAS).

Patients originating from study 201 (off-treatment phase)
	VS HBeAg (-) discontinue both n = 23	VS HBeAg (+) discontinue both n = 18
HBV DNA baseline, log₁₀ IU/ml	1.0 (0.11)	1.2 (0.16)
Change from baseline at end of off-treatment	3.6 (2.41)	4.8 (2.55)
HBV pgRNA baseline, log₁₀ U/ml	NA	1.5 (ND)^∗
Change from baseline at end of off-treatment	NA	4.7 (ND)^∗
HBV TNA baseline, log₁₀ U/ml	1.3 (0.00)	1.3 (0.06)
Change from baseline at end of off-treatment	2.6 (2.29)	4.0 (2.51)

Data shown are mean (SD).

FAS, full analysis set; NA, not applicable; ND, not determined; pgRNA, pregenomic RNA; TNA, total nucleic acids; VS, virologically-suppressed.

^∗

n = 1 with available pgRNA results.